[{"id":"12afa15f-7965-45d2-ae3a-ebcbd432c421","acronym":"","url":"https://clinicaltrials.gov/study/NCT04103853","created_at":"2021-01-18T20:04:18.339Z","updated_at":"2024-07-02T16:36:24.021Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT04103853","lead_sponsor":"Suzhou Kintor Pharmaceutical Inc,","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pruxelutamide (GT0918)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2021-09-24"}]